NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

ZVSA

ZyVersa Therapeutics Inc

Jul 08 • 04:00PM ET

0.7750

Dollar change +0.1147
Percentage change 17.37	%

Healthcare • Biotechnology • USA • NASD

Peers: VRTX REGN BMRN BIIB INCY NBIX IONS ALNY EXEL BLUE

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-7.78	Insider Own	0.25%	Shs Outstand	4.87M	Perf Week	14.46%
Market Cap	3.78M	Forward P/E	-	EPS next Y	-	Insider Trans	0.00%	Shs Float	4.86M	Perf Month	20.12%
Enterprise Value	2.17M	PEG	-	EPS next Q	-	Inst Own	7.28%	Short Float	3.89%	Perf Quarter	25.53%
Income	-8.84M	P/S	-	EPS this Y	-	Inst Trans	-80.23%	Short Ratio	0.05	Perf Half Y	-28.90%
Sales	0.00M	P/B	0.24	EPS next Y	-	ROA	-41.48%	Short Interest	0.19M	Perf YTD	-26.89%
Book/sh	3.17	P/C	2.35	EPS next 5Y	-	ROE	-91.39%	52W High	6.30 -87.70%	Perf Year	-78.53%
Cash/sh	0.33	P/FCF	-	EPS past 3/5Y	63.45% 58.00%	ROIC	-108.77%	52W Low	0.47 63.92%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	32.51% 16.18%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	99.56%	Oper. Margin	-	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	0.18	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	60.88	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.18	EPS Q/Q	83.97%	SMA20	14.40%	Beta	0.81	Target Price	20.00
Payout	-	Debt/Eq	0.00	Sales Q/Q	-	SMA50	23.68%	Rel Volume	50.68	Prev Close	0.66
Employees	7	LT Debt/Eq	0.00	Earnings	May 12 AMC	SMA200	-33.53%	Avg Volume	4.09M	Price	0.77
IPO	Feb 10, 2022	Option/Short	No / No	EPS/Sales Surpr.	- -	Trades		Volume	207,259,800	Change	17.37%

Today 12:30PM	ZyVersa Therapeutics Announces a Warrant Inducement Transaction for $2.0 Million in Gross Proceeds (GlobeNewswire) +17.37%
07:52AM	ZyVersa Therapeutics Supports FDA-Authorized Emergency Compassionate Use of Cholesterol Efflux Mediator VAR 200 in a Patient with ApoCII Amyloidosis (GlobeNewswire)
Jun-26-25 07:55AM	ZyVersa Therapeutics Announces First Clinical Site Activation, Initiating Patient Recruitment for Cholesterol Efflux Mediator VAR 200's Phase 2a Clinical Trial in Patients with Diabetic Kidney Disease (DKD) (GlobeNewswire)
Jun-25-25 07:55AM	ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator VAR 200 (GlobeNewswire) +7.58%
May-20-25 08:52AM	ZyVersa Therapeutics Highlights Published Study Reinforcing That Microglia-driven Inflammation Is Pivotal in Development of Parkinson's and Alzheimer's Diseases (GlobeNewswire)
04:35PM	Loading…
May-12-25 04:35PM	ZyVersa Therapeutics Reports First Quarter 2025 Financial Results and Highlights Pipeline Progress (GlobeNewswire)
May-07-25 07:57AM	ZyVersa Unveils Groundbreaking Potential of Inflammasome Inhibitors in Combination with GLP-1 Agonists to Address Unmet Medical Needs of People Living with Obesity; Provides R&D Update (GlobeNewswire) +24.24%
Apr-29-25 07:57AM	ZyVersa Therapeutics Announces Published Data Showing Inflammasome ASC Inhibitor IC 100 Decreases Microglial Inflammasome Activation and Alpha-Synuclein That Contribute to Neurodegeneration in Parkinson's Disease (GlobeNewswire)
Apr-24-25 07:57AM	ZyVersa Therapeutics CEO Issues Shareholder Letter Announcing Transformative R&D Trends for Inflammasome Inhibitors, and Provides Update on Inflammasome ASC Inhibitor IC 100's Development Status (GlobeNewswire)
Apr-10-25 09:23AM	Why ZyVersa Therapeutics, Inc. (ZVSA) Went Down On Thursday? (Insider Monkey) -25.12%
Apr-08-25 07:57AM	ZyVersa Therapeutics CEO Issues Shareholder Letter on PARASOL Recommendations Expected to Reduce Drug Development Barrier for Rare Kidney Disease, Focal Segmental Glomerulosclerosis (FSGS) (GlobeNewswire) +118.21%
Mar-27-25 09:15AM	ZyVersa Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire) -5.42%
Mar-18-25 07:57AM	ZyVersa Therapeutics Highlights Data Published in the Journal of the American Heart Association Demonstrating Inflammasome Inhibition Attenuates Obesity-Associated Cardiomyopathy in Animal Model Study (GlobeNewswire) -6.01%
Mar-12-25 07:57AM	ZyVersa Therapeutics Highlights Data Demonstrating Inflammasome Inhibition Reduces Neuroinflammation and Pathological Brain Deposition of Amyloid Beta in Alzheimer's Disease Mouse Model (GlobeNewswire) -13.74%
Mar-06-25 08:00AM	ZyVersa Therapeutics, Inc. Announces Pricing of $2.0 Million Private Placement Priced At The Market (GlobeNewswire) -5.73%
07:52AM	Loading…
Mar-05-25 07:52AM	ZyVersa Therapeutics Highlights Data Demonstrating NLRP3 Inflammasome Inhibition Reduces Inflammation, Improves Heart Function, and Restores Glucose Homeostasis and Insulin Sensitivity in Obese Animal Model of Heart Failure (HFpEF) and Type 2 Diabetes (GlobeNewswire) -12.58%
Dec-18-24 07:55AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Attend JPM's Healthcare Conference 2025 in San Francisco (GlobeNewswire) +9.45%
Nov-20-24 07:55AM	ZyVersa Therapeutics Announces Peer-Reviewed Publication Demonstrating That Inflammasome ASC Inhibitor IC 100 Protects Against Stroke-Related Cardiovascular Injury and Dysfunction in Preclinical Trial (GlobeNewswire) -6.50%
Nov-15-24 08:35AM	Life Sciences Investor Forum: Presentations Now Available for Online Viewing (GlobeNewswire)
Nov-14-24 08:10AM	ZyVersa Therapeutics Reports Third Quarter, 2024 Financial Results and Provides Business Update (GlobeNewswire) -9.60%
Nov-12-24 08:35AM	Life Sciences Investor Forum Agenda Announced for November 14th (GlobeNewswire)
Nov-05-24 07:00AM	ZyVersa Therapeutics Highlights Published Data Demonstrating the Potential of Inflammasome Inhibition to Protect Pancreatic Islet Beta Cells and Attenuate Progression from Obesity to Insulin Resistance and Type 2 Diabetes (GlobeNewswire) +39.56%
Oct-29-24 07:57AM	ZyVersa Therapeutics Highlights Review Article Supporting the Need for Drug Therapies to Treat the Inflammation of Obesity in Addition to Weight Loss Drugs (GlobeNewswire)
Oct-22-24 07:57AM	ZyVersa Therapeutics Highlights Published Data Demonstrating That Obesity Results in Neuroinflammation Implicated in Development of Neurodegenerative Diseases (GlobeNewswire)
Oct-17-24 07:50AM	ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Highlighting Obesity Development Plans for Inflammasome ASC Inhibitor IC 100 Over the Next Nine Months (GlobeNewswire)
Oct-15-24 07:50AM	ZyVersa Therapeutics CEO, Stephen C. Glover, Was a Featured Guest on The Big Biz Show to Discuss Current Trends in the Obesity Drug Market and the Potential Role of Inflammasome Inhibitors (GlobeNewswire)
Oct-07-24 07:55AM	ZyVersa Therapeutics Forms New Scientific Advisory Board to Support Development of Inflammasome ASC Inhibitor IC 100 for Obesity with Metabolic Complications (GlobeNewswire)
Aug-09-24 09:52PM	ZVSA Stock Earnings: ZyVersa Therapeutics Beats EPS for Q2 2024 (InvestorPlace) -5.63%
04:40PM	ZyVersa Therapeutics Reports Second Quarter, 2024 Financial Results and Provides Business Update (GlobeNewswire)
Aug-07-24 07:50AM	ZyVersa Therapeutics Announces Published Data Supporting the Rationale for Inhibiting Inflammasome ASC with IC 100 to Control Chronic Inflammation (GlobeNewswire)
07:45AM	Loading…
Jul-29-24 07:45AM	ZyVersa Therapeutics Announces Published Data Demonstrating That Plasma Levels of Inflammasome ASC Show Promise as Biomarker of Early Cognitive Changes in Older Adults (GlobeNewswire) -6.49%
Jul-25-24 07:57AM	ZyVersa Therapeutics Selects Obesity and Related Metabolic Complications as Lead Indication for Inflammasome ASC Inhibitor IC 100 (GlobeNewswire)
Jul-18-24 11:18AM	ZyVersa Therapeutics Announces Publication Demonstrating that Inflammasome ASC Inhibitor IC 100 Restored Retinal Structure and Function in a Retinopathy of Prematurity Animal Model (GlobeNewswire) -10.80%
Jul-09-24 07:57AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 3rd Annual Kidney Conference to be Held Virtually on July 15, 2024 (GlobeNewswire) +28.03%
May-15-24 11:53PM	ZVSA Stock Earnings: ZyVersa Therapeutics Misses EPS for Q1 2024 (InvestorPlace) -6.62%
08:35AM	ZyVersa Therapeutics Reports First Quarter, 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-14-24 07:57AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2024 BIO International Convention (GlobeNewswire)
Apr-29-24 07:57AM	ZyVersa Therapeutics Announces Publication Reinforcing the Rationale for Inhibiting ASC with IC 100 to Potentially Attenuate Cardiac Comorbidities in Patients with Alzheimer's Disease (GlobeNewswire) +15.63%
Apr-04-24 07:57AM	ZyVersa Therapeutics Highlights Published Data Demonstrating NLRP3 Inflammasome Inhibition Has Potential to Decrease Atherosclerotic Lesions in Patients with Diabetes (GlobeNewswire)
Mar-25-24 08:17AM	ZyVersa Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-18-24 07:57AM	ZyVersa Therapeutics Announces IRB Approval of Phase 2a Clinical Trial Protocol to Evaluate Cholesterol Efflux Mediator VAR 200 in Patients with Diabetic Kidney Disease (GlobeNewswire) +8.79%
Mar-14-24 07:57AM	ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in a Panel Discussion Titled Inflammation Illuminated, at Benzinga's Virtual Healthcare Summit 2024 on March 20, 2024 (GlobeNewswire)
Feb-29-24 07:57AM	ZyVersa Therapeutics Generated Approximately $2.7 Million From Exercise of Warrants Following Excitement Around News That Inflammasome Inhibitors Have Potential to Effectively Treat Obesity (GlobeNewswire) +10.00%
Feb-28-24 07:57AM	ZyVersa Therapeutics Highlights Data from Review Article Published in Nature Reinforcing IC 100's Rationale for Inhibiting ASC and ASC Specks to Attenuate Damaging Inflammation Associated with Various Conditions, Including Obesity and Its Complications (GlobeNewswire) -8.26%
Feb-26-24 07:55AM	Why Is ZyVersa Therapeutics (ZVSA) Stock Up 37% Today? (InvestorPlace) +34.83%
Feb-22-24 07:47AM	ZyVersa Therapeutics Publishes New White Paper Detailing the Role of Inflammasomes and ASC Specks in Neurological Diseases, and Data Supporting Inflammasome ASC Inhibitor IC 100 as a Potential Therapeutic Option (GlobeNewswire)
Feb-14-24 07:53AM	ZyVersa Therapeutics Highlights Review Article Substantiating That Inflammasome Activation Is Pathogenic in Multiple Neurological Diseases (GlobeNewswire)
Feb-07-24 08:02AM	ZyVersa Therapeutics' CEO, Stephen C. Glover to Present at the 2024 BIO CEO & Investor Conference to Provide Corporate Update and Discuss Key Milestones (GlobeNewswire)
Jan-31-24 07:57AM	ZyVersa Therapeutics Highlights Publication Indicating That Inflammasome NLRP3-Mediated Inflammation in Obese Children Leads to Insulin Resistance and Risk of Complications Such as Type 2 Diabetes (GlobeNewswire) -7.30%
Jan-24-24 07:57AM	ZyVersa Therapeutics Announces Peer-Reviewed Article Supporting the Therapeutic Potential of Targeting ASC Specks During Progression of Alzheimer's Disease (GlobeNewswire) +5.67%
Jan-17-24 01:31PM	Why Is Inflammatory Disease-Focused ZyVersa Therapeutics Stock Trading Higher Today? (Benzinga)
07:52AM	ZyVersa Therapeutics Highlights Peer-Reviewed Article Linking Inflammasome Activation to Triple-Negative Breast Cancer Brain Metastasis (GlobeNewswire)
Jan-10-24 08:06AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, Featured on Benzinga All Access (GlobeNewswire)
Jan-04-24 07:50AM	ZyVersa Therapeutics Announces Equity Research Coverage Initiated by Noble Capital Markets (GlobeNewswire)
Jan-03-24 08:07AM	ZyVersa Therapeutics CEO, Stephen C. Glover, Issues Letter to Shareholders Providing Outlook for 2024 (GlobeNewswire)
Dec-18-23 08:12AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in BIO Partnering @ JPM During J.P. Morgan Week 2024 (GlobeNewswire) +38.06%
Dec-14-23 07:01AM	ZyVersa Therapeutics Engages CRO, George Clinical, for Phase 2a Clinical Trial for Cholesterol Efflux Mediator VAR 200 (GlobeNewswire)
Dec-07-23 11:20AM	ZyVersa Therapeutics Announces Publication Demonstrating That Plasma Levels of NLRP3 Inflammasomes Correlate with Progression of Diabetic Kidney Disease in Patients with Type 2 Diabetes (GlobeNewswire) -46.26%
09:07AM	Why Is ZyVersa Therapeutics (ZVSA) Stock Down 44% Today? (InvestorPlace)
Dec-06-23 09:00PM	ZyVersa Therapeutics, Inc. Announces Pricing of $5.0 Million Public Offering (GlobeNewswire)
09:54AM	Why Is ZyVersa Therapeutics (ZVSA) Stock Up 27% Today? (InvestorPlace)
07:20AM	ZyVersa Therapeutics Announces Publication Showing AIM2 and NLRP3 Inflammasomes Promote Atherosclerosis in Diabetes, Supporting IC 100's Rationale for Targeting ASC to Inhibit Multiple Inflammasome Pathways (GlobeNewswire)
Nov-30-23 11:30AM	ZyVersa Therapeutics, Inc. Announces Reverse Stock Split and Increase in Authorized Shares of Common Stock (GlobeNewswire) -30.85%
Nov-14-23 04:35PM	ZyVersa Therapeutics Reports Third Quarter 2023 Corporate Update and Financial Results (GlobeNewswire) -9.68%
Nov-09-23 07:35AM	ZyVersa Therapeutics Announces Article Published in Peer-Reviewed Biomedical Journal Demonstrating That NLRP3 Inflammasome Inhibition Attenuates Inflammatory Bowel Disease Symptoms in Animal Model (GlobeNewswire)
Nov-06-23 07:05AM	ZyVersa Therapeutics Announces Article in Peer-Reviewed Journal, Ecotoxicology and Environmental Safety, Linking Air Pollution with Development and Progression of Chronic Kidney Disease That Can Be Attenuated by Inhibiting Inflammasome NLRP3 Activation (GlobeNewswire)
Nov-01-23 08:07AM	ZyVersa Therapeutics Announces Publication in Molecular Neurobiology Reinforcing Data Demonstrating That Inflammasome ASC Inhibitor IC 100 Attenuates the Inflammatory Response Causing Neuronal Damage in Multiple Sclerosis Model, Potentially Providing Neuroprotection (GlobeNewswire) +9.12%
Oct-25-23 06:50AM	ZyVersa Therapeutics Announces Research Published in the Peer-Reviewed Journal Diabetes Reinforcing IC 100's Rationale for Inhibiting ASC to Attenuate Damaging Inflammation Associated with Serious Conditions Such as Obesity-related Heart Disease (GlobeNewswire)
Oct-18-23 07:05AM	ZyVersa Therapeutics Announces a Publication in the Peer-Reviewed Journal, Aging, Linking Inflammasome NLRP3 Activation with Age-Related Structural Changes in the Kidney and Reduced Kidney Function (GlobeNewswire)
Oct-11-23 07:05AM	ZyVersa Therapeutics Announces Peer-Reviewed Publication in Nature Reviews Nephrology Substantiating VAR 200's Rationale for Mediating Transport of Cholesterol and Lipids Out of Kidney Cells to Attenuate Progression of Kidney Disease (GlobeNewswire) +10.40%
Oct-04-23 07:05AM	ZyVersa Therapeutics Announces New Peer-Reviewed Publication Reinforcing the Rationale for Inhibiting ASC Specks with IC 100 to Attenuate Spread of Inflammation into Surrounding Tissues (GlobeNewswire) -6.47%
Sep-27-23 07:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover to Participate in Panel at the BioFlorida Conference Discussing Inflammation and its Impact on Numerous Diseases (GlobeNewswire)
Sep-22-23 06:35AM	ZyVersa Therapeutics Announces Research Published in The Journal of Clinical Investigation Reinforcing IC 100s Rationale for Inhibiting ASC Specks to Attenuate Spread of Inflammation into Surrounding Tissues (GlobeNewswire)
Sep-12-23 06:30AM	ZyVersa Therapeutics Announces Research Published in Frontiers in Immunology Reinforcing IC 100s Rationale for Inhibiting Multiple Inflammasomes to Control Inflammation in Various Inflammatory Diseases (GlobeNewswire) +15.45%
Aug-21-23 04:15PM	ZyVersa Therapeutics Reports Second Quarter 2023 Corporate and Financial Results (GlobeNewswire) -6.52%
Jul-24-23 08:00AM	ZyVersa Therapeutics, Inc. Announces Pricing of $2.1 Million Public Offering (GlobeNewswire) -11.79%
Jul-17-23 07:38AM	ZyVersa Therapeutics Announces Publication in the Journal, Hepatology, Highlighting the Role of NLRP3 Inflammasome-Mediated IL-18 in Development of Liver Fibrosis (GlobeNewswire)
Jul-14-23 07:37AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, Is an Invited Speaker at H.C. Wainwright 2nd Annual Kidney Conference to be Held Virtually on July 25, 2023 (GlobeNewswire)
Jul-10-23 07:37AM	ZyVersa Therapeutics Announces Publication in the Journal Circulation That Demonstrates the Role of Inflammasome Activation in Hypertrophic Heart Disease Induced by Mechanical Stress (GlobeNewswire)
Jul-07-23 07:37AM	European Patent Granted for ZyVersa Therapeutics' Lead Asset, Cholesterol Efflux Mediator VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease (GlobeNewswire) +8.25%
Jun-28-23 07:37AM	ZyVersa Therapeutics Announces Publication in Clinical Immunology Demonstrating Association Between Renal NLRP3 Inflammasome Activation and Lupus Nephritis Disease Activity (GlobeNewswire)
Jun-20-23 04:07PM	ZyVersa Therapeutics Announces a Publication in Journal of the American Heart Association Linking NLRP3 Inflammasomes with Calcification in Arteries of Patients with Peripheral Arterial Disease (PAD) (GlobeNewswire) -11.79% -15.84%
Jun-13-23 08:07AM	ZyVersa Therapeutics Publishes New White Paper Detailing the Critical Role of Inflammasome ASC in Inflammatory Diseases, and Its Potential as a Therapeutic Target (GlobeNewswire)
Jun-06-23 09:07AM	European Patent Office to Grant ZyVersa Therapeutics Patent Application for Cholesterol Transport Mediator VAR 200 for Use in Patients with Diabetic Nephropathy/Diabetic Kidney Disease (GlobeNewswire)
May-25-23 09:07AM	ZyVersa Therapeutics Announces a Publication in Frontiers in Medicine Showing Direct Inflammasome Activation in Children with Juvenile Idiopathic Arthritis (GlobeNewswire) -5.88%
May-19-23 04:15PM	ZyVersa Therapeutics Announces Changes to ZyVersas Board of Directors (GlobeNewswire) +14.23% +13.22%
May-15-23 09:07AM	ZyVersa Therapeutics Announces Article Published in Metabolism Pointing to Glomerular Cholesterol Accumulation as Key Factor Exacerbating Renal Injury and Dysfunction in Diabetic Kidney Disease (GlobeNewswire) -6.00%
May-12-23 09:07AM	ZyVersa Therapeutics Reports First Quarter 2023 Corporate and Financial Results (GlobeNewswire) -7.23%
May-11-23 09:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in A.G.P.s Virtual Healthcare Conference (GlobeNewswire)
May-09-23 09:05AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Participate in the 2023 BIO International Convention (GlobeNewswire)
07:15AM	Sidoti's Micro-Cap Virtual May Conference (ACCESSWIRE)
May-04-23 09:07AM	ZyVersa Therapeutics Announces a Publication in Hepatology Revealing That Alcohol-induced Extracellular ASC Specks Perpetuate Liver Inflammation and Damage in Alcoholic Hepatitis (GlobeNewswire) +7.53%
May-01-23 06:30PM	ZyVersa Therapeutics, Inc. Announces Closing of $11.0 Million Public Offering (GlobeNewswire) +13.02%
Apr-27-23 09:07AM	ZyVersa Therapeutics' CEO, Stephen C. Glover, to Present at Sidoti Micro-Cap Virtual Conference (GlobeNewswire)
Apr-26-23 09:10AM	ZyVersa Therapeutics, Inc. Announces Pricing of $11.0 Million Public Offering (GlobeNewswire) -69.07%
Apr-25-23 09:07AM	ZyVersa Therapeutics Announces Publication of an Article in the Journal of Neuroinflammation Addressing the Role of ASC Specks in Propagation of Alpha-Synuclein Pathology in Parkinsons Disease (GlobeNewswire) -5.85%
Apr-24-23 09:07AM	ZyVersa Therapeutics Adds Dr. Douglas Golenbock to Its Inflammatory Disease Scientific Advisory Board to Support Advancement of Inflammasome ASC Inhibitor IC 100 (GlobeNewswire)
09:00AM	Keynotes, Educational Panels and 77 Companies to Present at the Planet MicroCap Showcase: VEGAS on April 25-27, 2023 at the Horseshoe Hotel & Casino in Las Vegas, NV (ACCESSWIRE)
Apr-19-23 09:07AM	ZyVersa Therapeutics Announces Article Published in Biomaterials Addressing the Critical Role of Inflammasome Activation in Neuroinflammation Resulting from Intracortical Implants (GlobeNewswire)
Apr-13-23 09:07AM	ZyVersa Therapeutics Announces Review Article Published in Frontiers in Pharmacology Addressing Microglial Inflammatory Activity as a Pharmacological Target in Mild Cognitive Impairment and Alzheimers Disease (GlobeNewswire)

ZyVersa Therapeutics, Inc. operates as a clinical stage biopharmaceutical company. It develops drugs for the treatment of renal and inflammatory diseases. The company was founded by Stephen C. Glover in 2014 and is headquartered in Weston, FL.

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ZVSA

ZyVersa Therapeutics Inc

Upgrade your FINVIZ experience